A Phase 3 interventional study of migalastat HCl 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Active, not recruiting at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 14th largest by planned enrollment, is the only one that started in 2022, is one of 11 in phase 3, and was the 17th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 14 is below the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 8 in phase 3, and was the 18th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
This is an open-label, non-comparative study for subjects with Fabry disease who have an estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFRMDRD) value of \< 30 mL/min/1.73 m2. Subjects may have had previous exposure to migalastat, either commercially or as a participant in a previous migalastat study.
Two distinct populations of subjects with Fabry disease and renal impairment will be enrolled into this study:
Subjects entering into this study will undergo screening (Visit 1) to confirm enrollment eligibility including confirmatory GLA genotyping. Subjects who meet eligibility criteria will have a Baseline Visit (Visit 2) within 30 days of screening. Subjects who do not meet eligibility criteria (eg, subjects with an eGFR > 30 mL/min/1.73 m2) may be re-screened.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.
Drug: migalastat HCl 150 mg
migalastat HCl 150 mg capsule
Also known as: migalastat, AT1001
Maximum observed concentration (Cmax)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Time to maximum concentration (tmax)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Apparent terminal elimination half-life (t½)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK
Time frame: Baseline through Month 12
Concentration at the end of a dosing interval at steady state (Ctrough)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Average plasma migalastat concentration over the dosing interval (Cavg)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Apparent plasma clearance (CL/F)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK
Time frame: Baseline through Month 12
Apparent terminal phase volume of distribution (Vz/F)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Dialysis clearance (CLD)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Volume of dialysate collected during the interval (VD)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Mean migalastat concentration in dialysate (CD)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Amount recovered in dialysate (AeD)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Fraction of the dose recovered in dialysate (FeD)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Mean migalastat plasma concentration during the dialysis interval (P)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Mean inlet area under the curve (AUCinlet)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Mean outlet area under the curve (AUCoutlet)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Extraction ratio (ED)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Dialyzer blood flow (QD)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Cumulative amount excreted over all collection intervals (Ae0-τ)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Renal clearance (CLr)
To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.
Time frame: Baseline through Month 12
Adverse events (AEs)
To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease.
Time frame: Baseline through Month 12
Change from baseline in estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFR MDRD)
To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease
Time frame: Baseline through Month 12
Change from baseline eGFR based on the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI)
To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease
Time frame: Baseline through Month 12
Change from baseline in plasma globotriaosylsphingosine (lyso-Gb3)
To evaluate the pharmacodynamics (PD) of migalastat in subjects with Fabry disease and severe renal impairment
Time frame: Baseline through Month 12
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.
Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat